Compare OPTU & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPTU | ENGN |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | Canada |
| Employees | N/A | 82 |
| Industry | Cable & Other Pay Television Services | |
| Sector | Telecommunications | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 770.5M | 647.1M |
| IPO Year | N/A | N/A |
| Metric | OPTU | ENGN |
|---|---|---|
| Price | $1.48 | $7.26 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $2.00 | ★ $22.17 |
| AVG Volume (30 Days) | ★ 1.7M | 171.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.38 | $2.66 |
| 52 Week High | $2.14 | $12.25 |
| Indicator | OPTU | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 40.08 | 28.28 |
| Support Level | N/A | $6.03 |
| Resistance Level | $1.97 | $7.33 |
| Average True Range (ATR) | 0.09 | 0.61 |
| MACD | 0.00 | -0.28 |
| Stochastic Oscillator | 36.63 | 9.26 |
Optimum Communications Inc acquired privately held US cable company Suddenlink in 2015 and Cablevision in 2016. Suddenlink's networks provide television, internet access, and phone services to roughly 4.5 million US homes and businesses located primarily in smaller markets, with major clusters in Texas, West Virginia, Idaho, Arizona, and Louisiana. Cablevision provides comparable services to about 5.5 million homes and businesses in the New York City metro area. Both regions now operate under the Optimum brand name. Altice Europe spun off Altice USA, which includes both the Suddenlink and Cablevision operations, to shareholders in 2018. Altice USA also owns News 12 Networks, which broadcasts local news in New York.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.